Assessment of Animal Trials Conducted on Protectivity of Potential Sub-unit and Recombinant Vaccines against Pasteurella multocida B:2
DOI:
https://doi.org/10.37591/rrjoi.v6i2.1273Abstract
Haemorrhagic septicaemia, caused by Pasteurella multocida serotypes B:2 and E:2, is an acute, fatal and septicaemic disease of bovines occurring as catastrophic epizootics in most tropical regions of Asia and Africa. As chemotherapeutic treatment of P. multocida infections is expensive and ineffective, prevention of disease outbreaks following immunization is the most potent tool. Although, various vaccine formulations as alum precipitated, oil adjuvant, multiple emulsion and live attenuated vaccines are currently used in the field for the prevention of disease, the ideal vaccine with better protection and long-lasting immunity is indispensable. In the present era of recombinant technology, various sub-units and recombinant vaccines have been trialed for the development of safe and efficacious vaccines. In the present review, we have assessed the immunization trials conducted in bovines as well as laboratory animals for the protectivity of several sub-unit and recombinant vaccine formulations against P. multocida B:2 using different routes of immunization and challenge. The sub-unit vaccines using outer membrane proteins (OMP) as immunogen in normal or iron-deficient conditions have been found quite protective as compared to other sub-unit immunogens. Among the recombinant OMP vaccines, rOmp87 in Freund’s adjuvant, rOmpH and rVacJ in higher concentration with adjuvant and rTbpA fragment number 1 showed higher protection in challenge studies. AroA mutant vaccines showed significant level of protection in trials where immunization and challenge route was same. A DNA vaccine expressing tbpA has also been trialled in mice showing higher protection when combined with interleukins.
Keywords: Animal Trials, haemorrhagic septicaemia, Pasteurella multocida, recombinant, sub-unit vaccines
Cite this Article
S. Kharb, S. Charan. Assessment of Animal Trials Conducted on Protectivity of Potential Sub-unit and Recombinant Vaccines against Pasteurella multocida B:2. Research and Reviews: Journal of Immunology. 2016; 6(2): 1–12p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
